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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The CISD2 gene has been related to life span control and mitochondrial
dysfunction in animals. In addition, inhibition of mitochondrial enzymes due to an accumula-
tion of beta-amyloid peptide has been related to Alzheimer’s disease (AD). This study aimed to
explore the association between sequence variants of the CISD2 gene and risk for AD, which
has not been explored previously.
Methods: This was a caseecontrol study involving a total of 276 patients with AD who were
recruited from three teaching hospitals in Taiwan from 2007 to 2010; 460 controls were
recruited from elderly individuals attending for health check-ups and volunteers in the hospital
during the same period of time. All participants were aged 60 years or older. Two haplotype-
tagging single nucleotide polymorphisms (htSNPs), rs223330 and rs223331, were selected fromave no conflicts of interest relevant to this article.
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628 C.-J. Hsieh et al.the CISD2 gene to test the association between their polymorphisms and the risk for dementia,
and how ApoE 34 status, sex, hypertension, and type 2 diabetes mellitus might modify this
association.
Results: rs223330 variant carriage was not associated with risk for AD [TT versus CC: adjusted
odds ratio (AOR)Z 0.98, 95% confidence interval (CI)Z 0.59e1.62; TC versus CC: AORZ 0.72,
95% CI Z 0.47e1.11]. Similar findings were observed for rs223331 (AA versus TT: AORZ 1.12;
AT versus TT: AORZ 0.99). In addition, hypertension significantly modified the association be-
tween rs223331 and risk for AD (p Z 0.005).Three common haplotypes (with a frequency of
99.8%) were observed for CISD2. Common CISD2 haplotypes were not associated with the risk
for AD.
Conclusion: Our findings suggested that CISD2 htSNPs are not associated with AD risk.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Dementia is characterized by a decline or loss of cognitive
function in the elderly.1 The prevalence of dementia ranged
from 2.5% to 4.4% in the elderly in Taiwan in the 1990s,2,3
second only to Japan in prevalence in Asian countries.
Alzheimer’s disease (AD), a neurodegenerative disease, is
themost common type of dementia. In the United States, AD
was ranked as the fifth leading cause of death in people aged
65 years or older in 2005.1 AD is currently incurable and will
affect one in 85 people worldwide by 2050.4 As the popu-
lation ages around the world, AD will become an important
health concern in the near future.
The CISD2 gene is primarily localized in themitochondria.
The gene encoding CISD2 is located on chromosome 4q24.
Experimental studies have showed that CISD2 deficiency
causes mitochondrial dysfunction via autophagic cell death
prior to neuronal degeneration.5,6 Because mitochondrial
dysfunction has been related to aging process including life
span control in mammals,7e9 and accumulation of beta-
amyloid peptide, a characteristic of AD, has been related
to the inhibition of mitochondrial enzymes,10e12 it is
possible that variations of the CISD2 gene may affect dis-
eases prevalent in the elderly, such as AD.
Because CISD2 plays an important role in aging processes
related to mitochondrial dysfunction, this study aimed to
explore the association between CISD2 polymorphisms and
risk for AD related to inhibition of mitochondrial enzymes,
which has not been previously explored. Vascular risk fac-
tors [e.g., hypertension, type 2 diabetes mellitus (DM), and
hypercholesterolemia] have been related to subsequent
cerebral vascular disease, vascular dementia, and AD.13,14
This study further assessed how these factors would
modify the association under investigation.
Materials and methods
Study population
This was a caseecontrol study involving a total of 276 pa-
tients with AD recruited from the neurology clinics of three
teaching hospitals, namely National Taiwan University
Hospital, En Chu Kong Hospital, and Cardinal Tien’s Hospital
in Taiwan, between 2007 and 2010. Healthy controls
(n Z 460) were recruited from elderly individuals under-
going health check-ups and volunteers in the same hospitalsduring the same period of time. All participants were aged
60 years or older. Patients with a history of depressive
disorder, Parkinson’s disease, hemorrhagic stroke, cerebral
infarction, or brain tumor were excluded. In addition, those
with dementia subtypes other than AD were excluded.
The study was approved by the institutional review
boards of the three teaching hospitals. Written informed
consent was obtained from each study participant. Consent
from the legal guardian or next of kin was obtained when
patients had serious cognitive impairment.
A self-reported questionnaire was administered to
collect information on demography, lifestyle (e.g., con-
sumption of tea or coffee and physical activity), and
vascular risk factors (e.g., hypertension, DM, and hyper-
cholesterolemia). Blood samples were obtained from each
participant for genotyping. After centrifugation, genomic
DNA was extracted from the buffy coat using QuickGene-
Mini80 system (Fujifilm, Tokyo, Japan) and then stored in a
freezer at e80C.
Evaluation of AD
The Mini-Mental State Examination (MMSE)15 was used to
assess cognitive function, in addition to clinical examina-
tions by one neurologist at each hospital. Dementia was
diagnosed according to the Diagnostic and Statistical
Manual of Mental Disorders ( 4th ed, text revision) (Amer-
ican Psychiatric Association, 2000).16 AD was determined by
the National Institute of Neurological and Communicative
Diseases and StrokedAlzheimer’s Disease and Related Dis-
orders Association criteria for probable AD.17 Brain mag-
netic resonance imaging or computer topography was used
to identify evidence of cerebral atrophy and to exclude
other causes of dementia such as hemorrhagic stroke,
cerebral infarction, or brain tumor.
Only participants without a cognitive complaint were
included in the control group, and the cognitive function of
healthy controls was assessed by using the Short Portable
Mental Status Questionnaire (SPMSQ)18 to exclude partici-
pants with possible dementia.
Selection of single nucleotide polymorphisms and
genotyping assay
Common single nucleotide polymorphisms (SNPs; frequency
 5%) in CISD2 were identified from the Han Chinese in
Table 1 Characteristics of the study population.
Variables Alzheimer’s disease (n Z 276) Control (n Z 460) p
Age (y), mean  SD 79.2  7.0 72.8  6.0 <0.0001
Female, n (%) 178 (64.5) 242 (52.6) 0.0016
Education, n (%)
<6 years 137 (50.2) 51 (11.1) <0.0001
6e12 years 96 (35.2) 183 (40.0)
>12 years 40 (14.7) 224 (48.9)
MMSE score (mean  SD) 17.9  6.1 NA
SPMSQ (number of errors) NA 0.10  0.39
Cigarette smoking, n (%) 64 (23.2) 80 (17.4) 0.06
Alcohol consumption, n (%) 34 (12.3) 51 (11.1) 0.62
Type 2 DM, n (%) 49 (17.8) 63 (13.7) 0.14
Hypertension, n (%) 105 (38.0) 245 (53.4) <0.0001
Hypercholesterolemia, n (%) 50 (18.3) 140 (30.6) 0.0003
ApoE 34 carrier, n (%) 110 (40.0) 69 (15.1) <0.0001
DM Z diabetes mellitus; MMSE Z Mini-Mental State Examination; NA Z not applicable; SD Z standard deviation; SPMSQ Z Short
Portable Mental Status Questionnaire.
CISD2 and risk for Alzheimer’s disease 629Beijing, China (CHB) genotype data of the International
HapMap Project (http://hapmap.ncbi.nlm.nih.gov).
Haplotype block was determined by Haploview (http://
www.broadinstitute.org/haploview/haploview) using the
modified Gabriel et al algorithm.19,20 Two haplotype-
tagging SNPs (htSNPs), rs223330 and rs223331, were
selected from common SNPs of CISD2 using the tagSNP
program21 with an r2 of 0.92. ApoE genotypes were deter-
mined using the assay developed by Chapman et al.22 The
TaqMan Assay (Applied Biosystems Inc., Foster City, CA,
USA) was used to determine the genotypes of the CISD2
htSNPs. The genotyping success rate was greater than 95%
for both SNPs. Quality control samples were replicates of
results from 5% of study participants, and the concordance
rate reached 100%.
Statistical analysis
The HardyeWeinberg equilibrium (HWE) test was per-
formed to examine possible genotyping error and selection
bias for each SNP among the controls. The expect-
ationemaximization algorithm was applied to estimate
haplotype frequencies using the tagSNP program.21 Logistic
regression models were used to estimate adjusted odds
ratios and 95% confidence intervals (CIs) for risk for AD in
participants carrying either one or two copies of the minor
allele of each SNP and each haplotype. Age, sex, education,
and ApoE 34 status were adjusted in the models as potential
confounders.Table 2 Characteristics of CISD2 haplotype tagging single nucle
rs no. Nucleotide change Location
Minor allele f
rs223330 C/T Intron 0.47
rs223331 T/A Intron 0.38
HWE Z HardyeWeinberg equilibrium.The type I error rate was controlled by the false dis-
covery rate, and the single multiple-degree-of-freedom
test (global test) for the association between CISD2 SNPs
or haplotypes and dementia risk. Given a significant global
test, haplotype- and SNP-specific tests can provide some
guidance on which variant(s) are contributing to the sig-
nificant global test.
We also tested the association between CISD2 poly-
morphisms and risk for AD stratified by ApoE 34 status, sex,
hypertension, and type 2 DM. SAS version 9.2 (SAS Institute,
Cary, NC, USA) was used for the statistical analyses. All
statistical tests were two-sided.Results
This study included 276 individuals with AD and 460 con-
trols (>99% Han Chinese). Compared with the controls
(Table 1), patients with AD were older (79.2 years old
versus 72.8 years old), included more females (64.5% versus
52.6%), had a lower education level (6 years: 50.2% versus
11.1%), had less history of hypertension (38.0% versus
53.4%), and hypercholesterolemia (18.3% versus 30.6%),
and included ApoE 34 carriers (40.0% versus 15.1%). Ciga-
rette smokers, alcohol consumption, and history of type 2
DM were similar between patients with AD and controls.
The MMSE score in the case group was 17.9  6.1 and the
number of errors by SPMSQ in the control group was
0.10  0.39.otide polymorphisms.
Controls Cases
requency HWE p Minor allele frequency HWE p
0.92 0.49 0.22
0.35 0.36 0.48
Table 3 CISD2 single nucleotide polymorphisms (SNPs) and risk for Alzheimer’s disease.
SNP Codominant model
0 copies 1 copy 2 copies
Case/control AOR Case/control AOR (95% CI) Case/control AOR (95% CI)
rs223330 79/128 1.00 126/230 0.72 (0.47e1.11) 71/101 0.98 (0.59e1.62)
rs223331 113/187 1.00 117/203 0.99 (0.67e1.46) 39/69 1.12 (0.64e1.96)
All models were adjusted for age, sex, and ApoE 34 status.
AOR Z adjusted odds ratios; CI Z confidence interval.
630 C.-J. Hsieh et al.Two htSNPs, rs223330 and rs223331, of CISD2 were
genotyped. The minor allele frequencies of the two SNPs
ranged from 36% to 49%, which were similar to the minor
allele frequencies of the CHB genotype data in the HapMap
database. All CISD2 SNPs were in HWE among controls
(Table 2). For each SNP, the genotype frequencies were not
significantly different by disease status (data not shown).
Variations of rs223330 were not associated with risk for
AD (TT versus CC: AOR Z 0.98, 95% CI Z 0.59e1.62; TC
versus CC: AOR Z 0.72, 95% CI Z 0.47e1.11). Similar
findings were observed for rs223331 (AA versus TT:
AOR Z 1.12, 95% CI Z 0.64e1.96; AT versus TT:
AOR Z 0.99, 95% CI Z 0.67e1.46) (Table 3).
The two htSNPs spanning CISD2 formed one block, which
was determined by the modified Gabriel et al. algo-
rithm19,20 (Fig. 1). Three common (frequency 5%) haplo-
types made up of these two SNPs were identified with aFigure 1 CISD2 linkage disequilibrium plot. This plot was
generated by Haploview program using the modified Gabriel
et al18,19 algorithm based on the data from this study. Three
common haplotypes (frequency 0.05) were identified for
CISD2 and formed one block. The level of pairwise D0, which
indicated the degree of linkage disequilibrium between two
SNPs, is shown in the linkage disequilibrium structure in red.
HAP Z haplotype.cumulated frequency of 99.8% in controls. None of the
common haplotypes was significantly associated with risk
for AD (Table 4).
Hypertension significantly modified the association be-
tween CISD2 polymorphisms and risk for AD (p Z 0.005;
Table 5). However, no significant association was observed
after stratification by hypertension status, and no signifi-
cant interactions were observed between any of the
vascular risk factor and CISD2 polymorphisms. No significant
interactions were observed for sex and other vascular risk
factors (type 2 DM and hypercholesterolemia; see
Supplementary Table 1 and Supplementary Table 2).
Among naturally menopausal females, CISD2 poly-
morphisms were not associated with risk for AD
(Supplementary Table 3); neither did ApoE 34 status modify
this association (Supplementary Table 3).
Discussion
This study found that the CISD2 SNPs rs223330 and rs223331
and their haplotypes were not associated with risk for AD.
ApoE 34 status, and some vascular risk factors (type 2 DM
and hypercholesterolemia) did not modify the association.
However, hypertension significantly modified the associa-
tion between rs223331 and the risk for AD.
Vascular risk factors (e.g., higher body mass index, hy-
pertension, hypercholesterolemia, DM, and cigarette
smoking) have previously been related to risk for AD.13,23e28
We found that hypertension significantly modified the as-
sociation between CISD2 polymorphisms and risk for AD.
However, no significant association was observed after
stratification by hypertension status, which was consistent
with previous studies, including a meta-analysis.29,30 Use of
medication for hypertension, for example angiotensin-
converting enzyme inhibitors,31 may show a neuro-
protective effect, which might counterbalance the effect
of genetic polymorphisms on the risk for AD. Another reason
may be that the participants recruited to this study were
survivors of the elderly population with elevated risk for
cardiovascular diseases. Therefore, they may carry geno-
types related to lower risk for hypertension.
This study had several strengths. The selection of a set
of representative htSNPs captured the majority of genetic
information of CISD2 (r2 Z 0.92). In addition, all patients
with AD were evaluated by brain imaging and neurologists
to minimize the possible misclassification of dementia
subtypes. Also, our study population was almost completely
composed of Han Chinese individuals in Taiwan (>99%), so
population stratification32 was not a concern.
Table 4 CISD2 haplotypes and risk for Alzheimer’s disease
Haplotype Frequency
among controls (%)
Codominant model (global test p Z 0.82)
0 copies 1 copy 2 copies
Case/control AOR Case/control AOR (95% CI) Case/control AOR (95% CI)
Hap1: TT 47.4 80/129 1.00 125/229 0.72 (0.47e1.11) 71/102 0.97 (0.59e1.61)
Hap2: CA 36.8 114/186 1.00 122/204 1.00 (0.67e1.48) 39/68 1.13 (0.64e1.99)
Hap3: CT 15.6 200/326 1.00 66/117 0.93 (0.61e1.43) 9/15 1.13 (0.39e3.28)
Cumulative frequency 99.8.
All models were adjusted for age, sex, and ApoE 34 status.
Global testing was testing for the null hypothesis that none of the haplotypes was associated with dementia risk.
AOR Z adjusted odds ratios; CI Z confidence interval.
Table 5 CISD2 SNPs and the risk of Alzheimer’s disease by ApoE 34 status and hypertension status.
SNP Codominant model p p interaction
0 copies 1 copy p 2 copies
Case/
control
AOR Case/
control
AOR (95% CI) Case/
control
AOR (95% CI)
rs223330
Non-ApoE 34
carrier
52/110 1.00 69/192 0.72 (0.43e1.21) 0.08 44/86 1.14 (0.63e2.07) 0.25 0.35
ApoE 34 carrier 26/17 1.00 57/37 0.85 (0.36e2.01) 0.90 27/15 0.79 (0.30e2.12) 0.72
Non-hypertension 50/58 1.00 79/100 0.64 (0.35e1.19) 0.49 42/55 0.59 (0.29e1.20) 0.31 0.64
Hypertension 29/70 1.00 47/129 0.81 (0.42e1.60) 0.12 29/46 1.61 (0.75e3.49) 0.09
rs223331
Non-ApoE 34
carrier
69/158 1.00 66/170 0.86 (0.54e1.39) 0.51 26/60 1.02 (0.53e1.95) 0.76 0.69
ApoE 34 carrier 44/29 1.00 51/31 1.28 (0.61e2.65) 0.83 12/9 1.37 (0.42e4.43) 0.73
Non-hypertension 70/93 1.00 70/86 1.24 (0.72e2.15) 0.91 27/35 1.65 (0.76e3.56) 0.29 0.005
Hypertension 43/94 1.00 47/116 0.84 (0.46e1.52) 0.99 12/34 0.70 (0.29e1.67) 0.51
All models were adjusted for age and sex.
AOR Z adjusted odds ratios; CI Z confidence interval.
CISD2 and risk for Alzheimer’s disease 631However, our study also had several limitations. First,
the information on vascular risk factors (e.g., DM, hyper-
tension, and hypercholesterolemia) was obtained from a
self-report questionnaire instead of medical charts. How-
ever, by a random sampling of 5% of all participants, a high
concordance rate (>95%) was found between self-reported
and medical record-confirmed vascular diseases. In addi-
tion, participants’ awareness of these major health issues
was asked for in the questionnaire if their disease had been
diagnosed by physicians.33e35
Second, medications for treating vascular diseases may
affect the course of AD.36 This information may not be
obtainable because our participants were recruited from
neurology clinics and were likely to attend other physicians
for treatment of cardiovascular or cerebrovascular diseases.
Third, for rs223330, with a minor allele frequency of
0.49, a relative risk of 0.80, and a Z 0.05, a total of 1246
cases were need to achieve a statistical power of 0.8 under
the assumption of a dominant model; with a minor allele
frequency of 0.36 for rs223331, a relative risk of 0.89, and a
desired power of 0.8 under aZ 0.05 under the assumption
of a dominant model, the number needed is 2041 cases, as
estimated by Quanto program.37 Therefore, a larger sample
size is needed to confirm our findings.Finally, as the sensitivity and specificity of SPMSQ are
66.7% and 100% for the community population reported in a
previous study,38 more sensitive instruments such as the
Montreal Cognitive Assessment39 to evaluate cognitive
function in controls may be considered in future studies in
addition to subjective complaints.
CISD2 htSNPs and haplotypes were not associated
with risk for AD. It is also possible that CISD2 poly-
morphisms are not involved in the pathologic pathway of
AD. Future large studies will be needed to confirm these
findings.Acknowledgments
Funding for this study was provided by National Science
Council grants: NSC 96-2314-B-002-197 and 97-2314-B-002-
168-MY3.
Appendix 1. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jfma.2013.02.012
632 C.-J. Hsieh et al.References
1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L,
Ganguli M, et al. Global prevalence of dementia: a Delphi
consensus study. Lancet 2005;366:2112e7.
2. Liu CK, Lin RT, Chen YF, Tai CT, Yen YY, Howng SL. Prevalence
of dementia in an urban area in Taiwan. J Formos Med Assoc
1996;95:762e8.
3. Liu HC, Fuh JL, Wang SJ, Liu CY, Larson EB, Lin KN, et al.
Prevalence and subtypes of dementia in a rural Chinese pop-
ulation. Alzheimer Dis Assoc Disord 1998;12:127e34.
4. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM.
Forecasting the global burden of Alzheimer’s disease. Alz-
heimers Dement 2007;3:186e91.
5. Chen YF, Kao CH, Chen YT, Wang CH, Wu CY, Tsai CY, et al. Cisd2
deficiency drives premature aging and causes mitochondria-
mediated defects in mice. Genes Dev 2009;23:1183e94.
6. Boucquey M, De Plaen E, Locker M, Poliard A, Mouillet-Richard S,
Boon T, et al. Noxp20 and Noxp70, two new markers of early
neuronal differentiation, detected in teratocarcinoma-derived
neuroectodermic precursor cells. J Neurochem 2006;99:657e69.
7. TrifunovicA,WredenbergA,FalkenbergM,SpelbrinkJN,RovioAT,
Bruder CE, et al. Premature ageing in mice expressing defective
mitochondrial DNA polymerase. Nature 2004;429:417e23.
8. KujothGC,HionaA,PughTD,SomeyaS,PanzerK,WohlgemuthSE,
et al. Mitochondrial DNA mutations, oxidative stress, and
apoptosis in mammalian aging. Science 2005;309:481e4.
9. Vermulst M, Wanagat J, Kujoth GC, Bielas JH, Rabinovitch PS,
Prolla TA, et al. DNA deletions and clonal mutations drive
premature aging in mitochondrial mutator mice. Nat Genet
2008;40:392e4.
10. Querfurth HW, Laferla FM. Alzheimer’s disease. N Engl J Med
2010;362:329e44.
11. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS,
et al. Mitochondrial abnormalities in Alzheimer’s disease. J
Neurosci 2001;21:3017e23.
12. Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta
accumulation and origin of plaques in Alzheimer’s disease.
Neurobiol Aging 2005;26:1235e44.
13. Chui H. Vascular dementia, a new beginning: shifting focus
from clinical phenotype to ischemic brain injury. Neurol Clin
2000;18:951e78.
14. Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ. Vascular risk
factors and Alzheimer’s disease: are these risk factors for
plaques and tangles or for concomitant vascular pathology that
increases the likelihood of dementia? An evidence-based re-
view. Alzheimers Res Ther 2012;3:36.
15. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A
practical method for grading the cognitive state of patients for
the clinician. J Psychiatr Res 1975;12:189e98.
16. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.
Text revision. Washington, DC: American Psychiatric Association;
2000.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D,
Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of
the NINCDS-ADRDA Work Group under the auspices of Depart-
ment of Health and Human Services Task Force on Alzheimer’s
Disease. Neurology 1984;34:939e44.
18. Pfeiffer E. A short portable mental status questionnaire for the
assessment of organic brain deficit in elderly patients. J Am
Geriatr Soc 1975;23:433e41.
19. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J,
Blumenstiel B, et al. The structure of haplotype blocks in the
human genome. Science 2002;296:2225e9.
20. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ.
Sequence variants of Toll-like receptor 4 and susceptibility to
prostate cancer. Cancer Research 2005;65:11771e8.21. Stram DO, Leigh Pearce C, Bretsky P, Freedman M,
Hirschhorn JN, Altshuler D, et al. Modeling and E-M estimation
of haplotype-specific relative risks from genotype data for a
case-control study of unrelated individuals. Hum Hered 2003;
55:179e90.
22. Chapman J, Estupinan J, Asherov A, Goldfarb LG. A simple and
efficient method for apolipoprotein E genotype determination.
Neurology 1996;46:1484e5.
23. Whitmer RA, Gunderson EP, Quesenberry Jr CP, Zhou J, Yaffe K.
Body mass index in midlife and risk of Alzheimer disease and
vascular dementia. Curr Alzheimer Res 2007;4:103e9.
24. Patterson C, Feightner JW, Garcia A, Hsiung GY, Macknight C,
Sadovnick AD. Diagnosis and treatment of dementia. 1: risk
assessment and primary prevention of Alzheimer disease.
CMAJ 2008;178:548e56.
25. Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk
factors for Alzheimer’s disease. Am J Geriatr Cardiol 2007;16:
143e9.
26. Stoll G, Jander S, Schroeter M. Inflammation and glial re-
sponses in ischemic brain lesions. Prog Neurobiol 1998;56:
149e71.
27. De La Torre JC. The vascular hypothesis of Alzheimer’s disease:
bench to bedside and beyond. Neurodegener Dis 2010;7:
116e21.
28. Roman GC. Vascular dementia prevention: a risk factor anal-
ysis. Cerebrovasc Dis 2005;20(Suppl. 2):91e100.
29. Forti P, Pisacane N, Rietti E, Lucicesare A, Olivelli V, Mariani E,
et al. Metabolic syndrome and risk of dementia in older adults.
J Am Geriatr Soc 2010;58:487e92.
30. Guan JW, Huang CQ, Li YH, Wan CM, You C, Wang ZR, et al. No
association between hypertension and risk for Alzheimer’s
disease: a meta-analysis of longitudinal studies. J Alzheimers
Dis 2011;27:799e807.
31. Hajjar IM, Keown M, Lewis P, Almor A. Angiotensin converting
enzyme inhibitors and cognitive and functional decline in pa-
tients with Alzheimer’s disease: an observational study. Am J
Alzheimers Dis Other Demen 2008;23:77e83.
32. Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA,
Patterson N, et al. Assessing the impact of population strati-
fication on genetic association studies. Nat Genet 2004;36:
388e93.
33. El Fakiri F, Bruijnzeels MA, Hoes AW. No evidence for marked
ethnic differences in accuracy of self-reported diabetes, hy-
pertension, and hypercholesterolemia. J Clin Epidemiol 2007;
60:1271e9.
34. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ.
Agreement between self-report questionnaires and medical
record data was substantial for diabetes, hypertension,
myocardial infarction and stroke but not for heart failure. J
Clin Epidemiol 2004;57:1096e103.
35. St Sauver JL, Hagen PT, Cha SS, Bagniewski SM, Mandrekar JN,
Curoe AM, et al. Agreement between patient reports of car-
diovascular disease and patient medical records. Mayo Clin
Proc 2005;80:203e10.
36. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of
vascular risk factors is associated with slower decline in Alz-
heimer disease. Neurology 2009;73:674e80.
37. Gauderman WJ. Sample size requirements for association
studies of gene-gene interaction. Am J Epidemiol 2002;155:
478e84.
38. Erkinjuntti T, Sulkava R, Wikstrom J, Autio L. Short Portable
Mental Status Questionnaire as a screening test for dementia
and delirium among the elderly. J Am Geriatr Soc 1987;35:
412e6.
39. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S,
Whitehead V, Collin I, et al. The Montreal Cognitive Assess-
ment, MoCA: a brief screening tool for mild cognitive impair-
ment. J Am Geriatr Soc 2005;53:695e9.
